BidaskClub downgraded shares of CytomX Therapeutics (NASDAQ:CTMX) from a buy rating to a hold rating in a report issued on Thursday, December 7th.
CTMX has been the subject of several other research reports. Wedbush began coverage on CytomX Therapeutics in a report on Thursday, September 7th. They issued an outperform rating and a $26.00 price target for the company. Zacks Investment Research cut CytomX Therapeutics from a buy rating to a hold rating in a report on Friday, November 10th. Oppenheimer restated a hold rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. Jefferies Group set a $25.00 price target on CytomX Therapeutics and gave the company a buy rating in a report on Friday, August 25th. Finally, Bank of America lifted their price target on CytomX Therapeutics from $30.00 to $34.00 and gave the company a buy rating in a report on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. The company has an average rating of Hold and a consensus target price of $31.88.
CytomX Therapeutics (NASDAQ:CTMX) traded down $0.96 on Thursday, reaching $21.11. The company’s stock had a trading volume of 268,937 shares, compared to its average volume of 384,989. The stock has a market cap of $847.68, a PE ratio of -13.28 and a beta of 0.47. CytomX Therapeutics has a 52 week low of $10.40 and a 52 week high of $24.67.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc lifted its position in CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 1,434 shares in the last quarter. Macquarie Group Ltd. acquired a new position in CytomX Therapeutics during the 3rd quarter worth approximately $107,000. Cubist Systematic Strategies LLC acquired a new position in CytomX Therapeutics during the 2nd quarter worth approximately $174,000. Goldman Sachs Group Inc. acquired a new position in CytomX Therapeutics during the 1st quarter worth approximately $190,000. Finally, Voya Investment Management LLC acquired a new position in CytomX Therapeutics during the 2nd quarter worth approximately $203,000. 63.13% of the stock is currently owned by institutional investors and hedge funds.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.